Tislelizumab plus thoracic radiotherapy before surgery for resectable non-small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 interventional trial enrolls adults with previously untreated, histologically confirmed resectable stage IB–IIIA NSCLC. Participants receive neoadjuvant tislelizumab combined with thoracic radiotherapy (3D-CRT or IMRT) followed by planned surgical resection. The study requires measurable disease per RECIST v1.1 and collection of PD-L1 pathology for biomarker analyses. Key outcomes include safety, tumor and pathological response, and surgical feasibility.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Fully understand the study and voluntarily sign the informed consent form (ICF);
* Aged 18-70 years, regardless of gender;
* Previously untreated, histologically confirmed resectable stage IB-IIIA NSCLC (AJCC 9th edition staging);
* At least one measurable lesion per RECIST v1.1 criteria;
* Willing to provide PD-L1 immunohistochemistry slides and corresponding pathology reports for biomarker evaluation;
* Presence of lesions suitable for radiotherapy as assessed by the study team;
* ECOG performance status of 0-1;
* Adequate organ function;
* Willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures;
* Sufficient pulmonary function to tolerate planned lung resection surgery, as assessed by a surgeon;
* Women of childbearing potential must have a negative serum pregnancy test within 3 days prior to the first dose. Both female participants of childbearing potential and male participants with partners of childbearing potential must agree to use highly effective contraception during the study and for 180 days after the last dose of the study drug.

Exclusion Criteria:

* Presence of locally advanced unresectable or metastatic disease;
* NSCLC involving the superior sulcus, large cell neuroendocrine carcinoma (LCNEC), or sarcomatoid tumors;
* Participants with known EGFR mutations or ALK translocations (non-squamous NSCLC subjects must have confirmed EGFR/ALK mutation status);
* Prior systemic anticancer therapy for early-stage NSCLC, including investigational drugs; Contraindications to radiotherapy or inability to undergo radiotherapy;
* History of (non-infectious) pneumonitis/interstitial lung disease requiring steroids or current pneumonitis/interstitial lung disease requiring steroid treatment;
* Known active tuberculosis (TB) history; Known active infection requiring systemic therapy; Any known or suspected autoimmune disease or immunodeficiency;
* Active hepatitis B infection; Administration of live vaccines within 30 days before the first dose;
* Grade ≥2 peripheral neuropathy;
* Prior treatment with PD-1/PD-L1 inhibitors or drugs targeting other T-cell receptors (e.g., CTLA-4, OX-40, etc.);
* History of severe hypersensitivity to monoclonal antibodies;
* Severe or uncontrolled underlying medical conditions;
* Any condition that, in the investigator's judgment, may confound study results, interfere with the subject's participation, or compromise the subject's best interest in the study.

Where it's running

• Jiangsu Northern People Hospital
  Yangzhou, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Buhai Wang
• Email: wbhself@163.com
• Phone: +8651487373012

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant fulzerasib followed by sintilimab plus platinum-doublet chemotherapy for resectable KRAS G12C-mutant NSCLC

  This will test whether giving fulzerasib first, then sintilimab with platinum-doublet chemotherapy before surgery helps people with resectable KRAS G12C‑mutant stage IB–IIIA non‑small cell lung cancer.

  Recruiting Phase 2 The First Affiliated Hospital of Guangzhou Medical University · Beijing and 2 other locations · NCT07492342

• Laparoscopic liver and spleen removal for small liver cancer in people with cirrhosis and enlarged spleen

  This study tests whether removing part of the liver and the spleen during one operation helps people with small liver cancers and hypersplenism by improving liver function and immune balance.

  Recruiting Northern Jiangsu People's Hospital · Yangzhou, Jiangsu · NCT07811687

• Vagus nerve–guided laparoscopic spleen removal with azygoportal disconnection

  This procedure tests whether a vagus nerve–guided laparoscopic spleen removal plus azygoportal disconnection helps people with cirrhosis, portal hypertension, and hypersplenism who have had gastroesophageal variceal bleeding.

  Recruiting Northern Jiangsu People's Hospital · Yangzhou, Jiangsu and 1 other locations · NCT07462091

• Apixaban for portal vein clots that appear more than a year after laparoscopic splenectomy

  This trial tests whether taking apixaban twice daily can treat portal vein blood clots that develop more than a year after laparoscopic splenectomy in people with cirrhosis.

  Recruiting Northern Jiangsu People's Hospital · Yangzhou, Jiangsu · NCT07461545

• Apixaban for portal vein thrombosis occurring more than one year after laparoscopic splenectomy and azygoportal disconnection

  This trial will try whether taking apixaban 2.5 mg twice daily can treat portal vein clots that appear more than a year after laparoscopic splenectomy and azygoportal disconnection in people with cirrhosis.

  Recruiting Northern Jiangsu People's Hospital · Yangzhou, Jiangsu · NCT07461532

• Hydrocortisone plus fludrocortisone for adults with septic shock

  This test will see if adding fludrocortisone to hydrocortisone helps adults with septic shock survive and recover circulation faster.

  Recruiting Phase 4 Northern Jiangsu People's Hospital · Yangzhou, Jiangsu · NCT07383103

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.